Evidence map›Paper›PMID 32150005›Full record

ArticleThe Pediatric infectious disease journal2020

Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.

Jessica E Ericson, John McGuire, Marian G Michaels, Adam Schwarz, Robert Frenck, Jaime G Deville, Swati Agarwal, Adam M Bressler, Jamie Gao, Tracy Spears and 4 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in The Pediatric infectious disease journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02689531 (Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02689531 completednot on this map

Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

TypeobservationalSponsorDuke UniversityRan2016 to 2018Enrolled7,530ConditionsPneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Jessica E EricsonFrom the Penn State College of Medicine, Hershey, Pennsylvania.
John McGuireSeattle Children's Hospital, Seattle, Washington.
Marian G MichaelsUPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Adam SchwarzChildren's Hospital of Orange County, Orange, California.
Robert FrenckCincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio.
Jaime G DevilleUCLA Mattel Children's Hospital, Los Angeles, California.
Swati AgarwalInova Children's Hospital, Falls Church, Virginia.
Adam M BresslerAtlanta Institute for Medical Research, Atlanta, Georgia.
Jamie GaoDuke Clinical Research Institute, Durham, North Carolina.
Tracy SpearsDuke Clinical Research Institute, Durham, North Carolina.
Daniel K BenjaminFrom the Penn State College of Medicine, Hershey, Pennsylvania.
P Brian SmithFrom the Penn State College of Medicine, Hershey, Pennsylvania.
John S BradleyFrom the Penn State College of Medicine, Hershey, Pennsylvania.
Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee and the Clinical Trials Transformation Initiative
Penn State Milton S. Hershey Medical Center · USClinical Research Institute · USChildren's Hospital of Orange County · USChildren's Hospital of Pittsburgh · USCincinnati Children's Hospital Medical Center · USInova Children's Hospital · USInstitute for Medical Research · USMattel Children's Hospital · USSeattle Children's Hospital · US

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Increasing the Quality and Efficiency of Clinical Trials (R18)R18FD005292 · FDA · DUKE UNIVERSITY · PI LI, JENNIFER S · 2014 to 2019
$26.8M
Penn State Institutional Career Development CoreKL2TR002015 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI VAN SCOY, LAUREN JODI · 2016 to 2025
$7.8M
FDA HHS R18 FD005292FDA HHS U18 FD005292NCATS NIH HHS KL2 TR002015NCATS NIH HHS UL1 TR002014NIAAA NIH HHS HHSN275201000003CNICHD NIH HHS HHSN267200700051CNICHD NIH HHS HHSN275201000001GNICHD NIH HHS HHSN275201000003I
6 · The paper itself

Abstract

backgroundClinical trials for antibiotics designed to treat hospital-acquired and ventilator-associated bacterial pneumonias (HABP/VABP) are hampered by making these diagnoses in a way that is acceptable to the United States Food and Drug Administration and consistent with standards of care. We examined laboratory and clinical features that might improve pediatric HABP/VABP trial efficiency by identifying risk factors predisposing children to HABP/VABP and describing the epidemiology of pediatric HABP/VABP.

methodsWe prospectively reviewed the electronic medical records of patients <18 years of age admitted to intensive and intermediate care units (ICUs) if they received qualifying respiratory support or were started on antibiotics for a lower respiratory tract infection or undifferentiated sepsis. Subjects were followed until HABP/VABP was diagnosed or they were discharged from the ICU. Clinical, laboratory and imaging data were abstracted using structured chart review. We calculated HABP/VABP incidence and used a stepwise backward selection multivariable model to identify risk factors associated with development of HABP/VABP.

resultsA total of 862 neonates, infants and children were evaluated for development of HABP/VABP; 10% (82/800) of those receiving respiratory support and 12% (103/862) overall developed HABP/VABP. Increasing age, shorter height/length, longer ICU length of stay, aspiration risk, blood product transfusion in the prior 7 days and frequent suctioning were associated with increased odds of HABP/VABP. The use of noninvasive ventilation and gastric acid suppression were both associated with decreased odds of HABP/VABP.

conclusionsFood and Drug Administration-defined HABP/VABP occurred in 10%-12% of pediatric patients admitted to ICUs. Risk factors vary by age group.

Indexed as

AdolescentAge FactorsAnti-Bacterial AgentsCase-Control StudiesChildChild, PreschoolFemaleHospitalizationHumansInfantInfant, NewbornMalePneumonia, BacterialPneumonia, Ventilator-AssociatedProspective StudiesAnti-Bacterial Agents

Identifiers

PMID32150005
PMCPMC8293907
OpenAlexW3012192817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.